MET抑制剂在晚期肝癌中的应用进展(5)
[30] Abou-Alfa GK， Cheng AL，et al. Phase 3 randomized，double-blind， controlled study of cabozantinib (XL184) versus placebo in subjects with hepatocellular carcinoma who have received prior sorafenib (CELESTIAL； NCT01908426)[J]. J Clin Oncol ......
您现在查看是摘要页，全文长 1525 字符。